Skip to content

Comparision of the benefits and harm of indacaterol acetate and glycopyronium bromide with salmetrol and fluticasone in bronchial asthma patients.

To assess and compare the efficacy and safety of indacaterol acetate and glycopyrronium bromide with salmetrol and fluticasone in patients of bronchial asthma.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014079
Enrollment
50
Registered
2018-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Bronchial asthma

Interventions

Intervention1: Group 1: Indacatrol (150µg)+ Glycopyrronium (50µg) once a day for one month Control Intervention1: Group 2: Salmetrol (50µg) + Fluticasone (500µg) twice a day for one month

Sponsors

Aligarh Muslim University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients of stable asthma diagnosed clinically and spirometrically with complaints of chest tightness and coughing particularly at night or in the early morning. 2.All patients with documented diagnosis of asthma for a period of at least 1 year as per GINA guideline.

Exclusion criteria

Exclusion criteria: 1. Patients who had an asthma attack/exacerbation requiring systemic steroid/hospitalization. 2. Patients whoever had required intubation for severe asthma. 3. Patientâ??s clinical condition worsened by ICS administration. 4. Patients with a history of chronic lung disease other than asthma i.e. COPD, Sarcoidosis ,ILD

Design outcomes

Primary

MeasureTime frame
SpirometryTimepoint: 0, 3rd, 7th, 14th & 28th day

Secondary

MeasureTime frame
Renal function test, Hemogram,Liver function testTimepoint: 0 & 28th day

Countries

India

Contacts

Public ContactDr Md Hanzalah

Jawaharlal Nehru Medical College, Aligarh Muslim University

naseer_bettiah@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026